EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study

Sofie Johansson Alm iD, Bea Tornberg, Erik Delsing Malmberg, Henrik Hasle, Kristian Løvvik Juul-Dam iD, Lars Palmqvist, Borhan R Saeed iD, Giti Shah Barkhordar, Anastasia Soboli, Anna Staffas iD, Jonas Abrahamsson, Linda Fogelstrand

Pediatric Blood & Cancer · 2026-08 · 73 (8)

DOI: 10.1002/1545-5017.70397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 18.05.2026. Verfasst von Sofie Johansson Alm und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, High-Throughput Nucleotide Sequencing, Neoplasm, Residual. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish state under the agreement between the Swedish government and the county councils; the ALF-agreement, Barncancerfonden, Sahlgrenska University Hospital Research Foundations.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 ( FLT3 ‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3 ‐ITD during and after treatment has shown prognostic value in adults, but its clinical value in children remains unexplored. Procedure This study evaluated the potential of MRD analysis with deep sequencing (ultrahigh‐sensitivity next‐generation sequencing; UHS‐NGS) of FLT3 ‐ITD to assess treatment response and predict impending relapse in children with AML. A total of 168 samples from 17 patients (median age 11 years, range: 4–17) were analyzed. Bone marrow samples were used for evaluation of treatment response, and peripheral blood samples for post‐treatment monitoring.

Results

Deep sequencing enabled monitoring of the kinetics of FLT3 ‐ITD subclones throughout treatment. When used for post‐treatment monitoring, deep sequencing detected increasing levels of FLT3 ‐ITD in peripheral blood only in patients who relapsed, while no such increase was detected in patients in continuous complete remission. Comparisons with flow cytometry and deep sequencing of other mutations confirmed the sensitivity of the assay and the often subclonal nature of FLT3 ‐ITD.

Conclusions

Deep sequencing of FLT3 ‐ITD is a highly sensitive method for MRD monitoring in children with AML, with significant potential for assessing treatment response and detecting imminent relapse at an early stage. It may serve as a valuable molecular MRD method, especially as a complement to flow cytometry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteHigh-Throughput Nucleotide SequencingNeoplasm, ResidualTandem Repeat SequencesHumansChildChild, PreschoolFemaleMaleAdolescentPrognosisMutationFollow-Up Studies

Stichwörter der Autor:innen

FLT3‐ITDchildhood acute myeloid leukemiadeep sequencingmeasurable residual disease

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
  • Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
  • Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany.
  • Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.

ORCID-Profile: Sofie Johansson Alm, Kristian Løvvik Juul-Dam, Borhan R Saeed, Anna Staffas

Förderung

  • Swedish state under the agreement between the Swedish government and the county councils; the ALF-agreement
  • Barncancerfonden
  • Sahlgrenska University Hospital Research Foundations
  • Stiftelsen Assar Gabrielssons Fond

Zitieren

APA

Alm, S. J., Tornberg, B., Malmberg, E. D., Hasle, H., Juul-Dam, K. L., Palmqvist, L., Saeed, B. R., Barkhordar, G. S., Soboli, A., Staffas, A., Abrahamsson, J., & Fogelstrand, L. (2026). Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study. Pediatric Blood & Cancer, 73(8). https://doi.org/10.1002/1545-5017.70397

Vancouver

Alm SJ, Tornberg B, Malmberg ED, Hasle H, Juul-Dam KL, Palmqvist L, et al. Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study. Pediatric Blood & Cancer. 2026;73(8). doi:10.1002/1545-5017.70397

BibTeX
@article{Alm2026,
  author = {Alm, Sofie Johansson and Tornberg, Bea and Malmberg, Erik Delsing and Hasle, Henrik and Juul-Dam, Kristian Løvvik and Palmqvist, Lars and Saeed, Borhan R and Barkhordar, Giti Shah and Soboli, Anastasia and Staffas, Anna and Abrahamsson, Jonas and Fogelstrand, Linda},
  title = {Deep Sequencing of FLT3 ‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {8},
  doi = {10.1002/1545-5017.70397}
}
Kostenlos starten →